Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)
2021年9月15日 更新者:Dilip V. Jeste、University of California, San Diego
Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)
Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population.
The goals of the proposed study are to implement a multimodal lifestyle intervention to reduce that risk in these individuals living in residential care facilities, a common housing modality for people with serious mental illnesses.
If successful, this intervention will lead to reduction in excess medical comorbidity and mortality in persons with serious mental illnesses.
調査の概要
状態
募集
詳細な説明
Serious mental illnesses (SMI), including schizophrenia, bipolar disorder, and schizoaffective disorder, are associated with increased medical comorbidity and premature mortality from diabetes and cardiovascular disease.
Unhealthy lifestyles, including energy-dense (obesogenic) diet, sedentary behavior, and cigarette smoking are important risk factors for diabetes and accelerated biological aging.
All of these risk factors are potentially modifiable.
There is considerable literature documenting the effectiveness of strategies to prevent and manage diabetes in the general population; yet, these interventions are rarely offered to people with SMI.
Residential Care Facilities (RCFs), called Board-and-Care Homes in California, are a common housing modality for patients with SMI; they provide a venue that can maximize efficiency and sustainability of a lifestyle intervention.
The goals of the proposed four-year study are to tailor a multi-component intervention to this high-risk group.
The study will be a hybrid effectiveness-implementation (Hybrid Type 1) trial of a Multi-component Intervention for Diabetes risk reduction in Adults with SMI (MIDAS) in licensed RCFs in San Diego county.
As a Hybrid Type 1 study, the primary emphasis will be on determining the effectiveness of the intervention to achieve desired health outcomes while also systematically collecting data on its implementation within RCFs that will inform implementation strategy refinement.
Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs.
The RCFs will be divided randomly into four cohorts of three RCFs each.
Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15).
All the study participants will be assessed quarterly during the 15-month period.
Our investigators will train RCF staff (especially the Activity Director and cook) to increase physical activity and reduce smoking, and to implement healthful dietary modifications among the residents, using evidence-based interventions.
During the intervention phase, the RCF Activity Director will conduct twice-weekly manualized group sessions on education about diabetes, nutrition, exercise, and smoking cessation/reduction, to deliver a multi-component group intervention.
We will also explore if there are improvements in blood-based research biomarkers of insulin resistance and inflammation in the RCF residents with SMI.
This project is responsive to RFA-MH-17-608, and related to NIMH Strategic Objective #3.3B: testing interventions for effectiveness in community practice settings.
If successful, MIDAS will be sustained and disseminated, and would lead to reduction in excess medical comorbidity and mortality associated with SMI.
研究の種類
介入
入学 (予想される)
210
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Dilip V Jeste, MD
- 電話番号:(858) 534-4020
- メール:djeste@ucsd.edu
研究連絡先のバックアップ
- 名前:Danielle K Glorioso, LCSW
- 電話番号:(858) 246-0767
- メール:dglorioso@ucsd.edu
研究場所
-
-
California
-
La Jolla、California、アメリカ、92093
- 募集
- University of California, San Diego Division of Geriatric Psychiatry
-
コンタクト:
- Danielle K Glorioso, LCSW
- 電話番号:858-246-0767
- メール:dglorioso@ucsd.edu
-
コンタクト:
- Cynthia Ibarra, MA
- 電話番号:(858) 822-6005
- メール:cyibarra@ucsd.edu
-
主任研究者:
- Dilip V Jeste, MD
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年~65年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Participants: A total of 12 RCFs (30 to 45 beds each), 210 resident participants, and 120 staff members (1 manager, 2 activity directors, 1 cook, and 6 other staff members per facility) will be enrolled.
Inclusion and Exclusion Criteria:
Residential Care Facilities (RCFs):
Inclusion Criteria:
- Licensed by California Division of Social Services' Community Care Licensing
- Serves only individuals with SMI
- Has >15 residents currently living in the facility
- Willing to participate
Staff Participants:
Inclusion Criteria:
- Age >21 years
- Fluent in English
- Written informed consent to participate
Exclusion Criteria:
(1) Plans to leave the RCF during the next year.
Resident Participants:
Inclusion Criteria:
- Age 18 - 65 years
- Chart diagnosis of an SMI, mainly schizophrenia, schizoaffective disorder, or bipolar disorder
- Current treatment with antipsychotics
- Fluent in English
- Written informed consent to participate in this study
Exclusion Criteria:
- Chart diagnosis of dementia or intellectual disability disorder
- Active substance abuse (non-tobacco)
- Medical problems that interfere with ability to complete assessments and intervention
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:Control Phase
3-month initial control phase (no intervention, month 1-3)
|
|
|
実験的:Intervention Phase
6-month intervention phase - MIDAS Intervention Delivered.
Followed by 6-month follow-up phase (no intervention, months 10-15).
|
Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Body Mass Index (BMI in kg/m^2)
時間枠:Baseline to 9 months and sustained at 15 months
|
Change in Body Mass Index
|
Baseline to 9 months and sustained at 15 months
|
|
Waist Circumference
時間枠:Baseline to 9 months and sustained at 15 months
|
Change in Waist Circumference
|
Baseline to 9 months and sustained at 15 months
|
|
Fasting Glucose
時間枠:Baseline to 9 months and sustained at 15 months
|
Change in Fasting Glucose
|
Baseline to 9 months and sustained at 15 months
|
|
Hemoglobin A1c or HbA1c
時間枠:Baseline to 9 months and sustained at 15 months
|
Change in Hemoglobin A1c or HbA1c
|
Baseline to 9 months and sustained at 15 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Diet/Nutrition - Plasma Carotenoid Levels
時間枠:Baseline to 9 months and sustained at 15 months
|
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.Nutrition Data Systems for REsearch (NDS-R) Protocol
|
Baseline to 9 months and sustained at 15 months
|
|
Diet/Nutrition - Serum Lipid Levels
時間枠:Baseline to 9 months and sustained at 15 months
|
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.
|
Baseline to 9 months and sustained at 15 months
|
|
Objective Measure of Physical Activity
時間枠:Baseline to 9 months and sustained at 15 months
|
For 7 days during each assessment period, participants will wear the GT3X+ Actigraph, which measures movement and intensity of activity, and has good validation with VO2max.
It provides estimates of activity by seconds, that can be categorized into minutes spent in sedentary, light, moderate, and vigorous activity using calibration thresholds.
|
Baseline to 9 months and sustained at 15 months
|
|
Smoking - Expired Breath Carbon Monoxide (CO) Levels
時間枠:Baseline to 9 months and sustained at 15 months
|
Change in Smoking - Objective Measure of Cigarette Use: Expired Breath Carbon Monoxide (CO) level (parts per million) is measured with a handheld device.
CO monitoring is used primarily as a check on recent smoking, though it has also been used to indicate reductions in smoking.
|
Baseline to 9 months and sustained at 15 months
|
|
Smoking - Change in Smoking through Recall
時間枠:Baseline to 9 months and sustained at 15 months
|
Change in Smoking - Quantity and frequency of cigarette use for the prior week using a timeline followback procedure.
Smoking reduction calculated by % change in average cigarettes/day across assessments.
|
Baseline to 9 months and sustained at 15 months
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2018年12月28日
一次修了 (予想される)
2022年5月31日
研究の完了 (予想される)
2022年5月31日
試験登録日
最初に提出
2018年7月5日
QC基準を満たした最初の提出物
2018年8月9日
最初の投稿 (実際)
2018年8月13日
学習記録の更新
投稿された最後の更新 (実際)
2021年9月17日
QC基準を満たした最後の更新が送信されました
2021年9月15日
最終確認日
2021年9月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。